Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX19.390,04+0,87 %

Gold2.656,990,00 %

Öl (Brent)79,04-0,57 %

Dow Jones42.865,63+0,97 %

US Tech 10020.269,38+0,14 %

EUR/USD1,09379+0,02 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

X4 Pharmaceuticals Aktie

Aktie

ISIN: US98420X1037 WKN: A2PFVY SYM: 48Q Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,4672

EUR

-1,81 %

-0,0086 EUR

Letzter Kurs 11.10.24 Tradegate

Geldkurs

11.10.24

0,4548

EUR

3.298 STK

Briefkurs

11.10.24

0,4794

EUR

3.128 STK

X4 Pharmaceuticals Aktie kaufen

Neueste Nachrichten

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 01.10.24 · globenewswire · X4 Pharmaceuticals
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 03.09.24 · globenewswire · X4 Pharmaceuticals
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences 28.08.24 · globenewswire · X4 Pharmaceuticals
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates 08.08.24 · globenewswire · X4 Pharmaceuticals
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 01.08.24 · globenewswire · X4 Pharmaceuticals
X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024 30.07.24 · globenewswire · X4 Pharmaceuticals
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial 27.06.24 · globenewswire · X4 Pharmaceuticals
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 03.06.24 · globenewswire · X4 Pharmaceuticals
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia 29.05.24 · globenewswire · X4 Pharmaceuticals
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference 13.05.24 · globenewswire · X4 Pharmaceuticals
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility 09.05.24 · globenewswire · X4 Pharmaceuticals
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates 07.05.24 · globenewswire · X4 Pharmaceuticals

1
2
…
3

Meistgelesen

30 Tage
12 Monate

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 108 Leser

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates 848 Leser
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference 308 Leser
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated ... 300 Leser
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides ... 260 Leser
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority ... 240 Leser
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 220 Leser
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial ... 180 Leser
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 172 Leser
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 172 Leser
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences 164 Leser